Study of SPATA31C2: Protein of Interest as Drug Target Or Biomarker

Target Name: SPATA31C2

NCBI ID: G645961

SPATA31C2

Study of SPATA31C2: Protein of Interest as Drug Target Or Biomarker

SPATA31C2 (Protein FAM75C2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SPATA family of proteins, which are known for their role in gene regulation and DNA damage repair. In recent years, researchers have become interested in studying SPATA31C2 and its potential as a drug target or biomarker.

SPATA31C2 has been shown to play a role in a variety of biological processes, including cell growth, apoptosis (programmed cell death), and inflammation. It has also been shown to interact with a variety of molecules, including DNA, RNA, and proteins. These interactions make SPATA31C2 an attractive target for drugs that aim to modulate gene expression or cellular behavior.

One of the key challenges in studying SPATA31C2 is its complex structure. SPATA31C2 is a 21-kDa protein that contains 10 known domains. These domains include an N-terminal transmembrane domain, a coiled-coil domain, a zinc finger domain, and a C -terminal Tudor domain. The transmembrane domain is thought to play a role in SPATA31C2's localization to various cell types and interfaces, while the coiled-coil domain is thought to contribute to its stability and functions. The zinc finger domain is known for its role in protein-protein interactions, and the C-terminal Tudor domain is thought to play a role in SPATA31C2's stability and functions.

SPATA31C2 has also been shown to contain a number of potential drug targets. For example, SPATA31C2 has been shown to interact with the protein p53, which is a well-known tumor suppressor protein. This interaction suggests that SPATA31C2 may play a role in regulating cellular processes that are important for tumor growth and development. Additionally, SPATA31C2 has been shown to interact with the protein NF-kappa-B, which is a transcription factor that is involved in inflammation and cellular signaling. This interaction suggests that SPATA31C2 may play a role in modulating cellular responses to inflammation and other signaling pathways.

SPATA31C2 is also of interest as a potential biomarker for a variety of diseases. For example, SPATA31C2 has been shown to be expressed in the brains of individuals with Alzheimer's disease, a condition characterized by progressive memory loss and other neurological symptoms. This suggests that SPATA31C2 may be a useful biomarker for diagnosing or predicting the development of Alzheimer's disease. Additionally, SPATA31C2 has been shown to be expressed in the hearts of individuals with heart failure, a condition characterized by progressive muscle weakness and other symptoms. This suggests that SPATA31C2 may be a useful biomarker for diagnosing or predicting the development of heart failure.

In conclusion, SPATA31C2 is a protein that is of interest as a drug target or biomarker. Its complex structure and interactions with other molecules make it an attractive target for drugs that aim to modulate gene expression or cellular behavior. Additionally, its involvement in a variety of biological processes makes it a promising target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of SPATA31C2 in cellular processes and its potential as a drug target or biomarker.

Protein Name: SPATA31 Subfamily C Member 2

Functions: May play a role in spermatogenesis

The "SPATA31C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA31C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets